Search

Your search keyword '"Carrera C"' showing total 1,153 results
Start Over Author "Carrera C"
1,153 results on '"Carrera C"'

5. Análisis multicéntrico del manejo quirúrgico y tratamiento adyuvante de los pacientes con melanoma y positividad en la biopsia selectiva del ganglio centinela

Author

Samaniego-González, E., Podlipnik, S., Ribero, S., Nagore, E., Boada, A., Cañueto, J., Paradela, S., de Unamuno, B., Rodríguez-Jiménez, P., Puig, S., Malvehy, J., Carrera, C., Roccuzzo, G., Requena, C., Manrique-Silva, E., Richarz, N., Ruiz-Villanueva, A., Traves, V., España-Fernández, S., Botella-Estrada, R., González-Morán, M.A., and Tejera-Vaquerizo, A.

Published
2024
Full Text
View/download PDF

6. Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY

Author

Araujo-Castro, M., García Sanz, I., Mínguez Ojeda, C., Calatayud, M., Hanzu, F., Mora, M., Vicente, A., Blanco Carrera, C., De Miguel Novoa, P., López García, M. del Carmen, Manjón-Miguélez, L., Rodríguez de Vera, P., del Castillo Tous, M., Barahona San Millán, R., Recasens, M., Tomé Fernández-Ladreda, M., Valdés, N., Gracia Gimeno, P., Robles Lazaro, C., Michalopoulou, T., Álvarez Escolá, C., García Centeno, R., and Lamas, C.

Published
2023
Full Text
View/download PDF

7. Long‐term effectiveness and tolerability of apremilast in patients with moderate‐to‐severe plaque psoriasis: A 5‐year multicentre retrospective study—IL PSO (Italian landscape psoriasis).

Author

Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Balato, A., Bardazzi, F., Burlando, M., Carrera, C. G., Dapavo, P., Dini, V., Gaiani, F. M., Girolomoni, G., Guarneri, C., Lasagni, C., Loconsole, F., Marzano, A. V., Maurelli, M., Megna, M., Travaglini, M., and Costanzo, A.

Published
2024
Full Text
View/download PDF

10. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

Author

Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, Costanzo, Antonio, Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, and Costanzo, Antonio

Abstract

Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician's Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index. Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. Moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index (DLQI), signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.

Published
2024

11. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra, Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, and Narcisi, Alessandra

Abstract

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.

Published
2024

12. Profilo super responder in corso di trattamento con bimekizumab: studio retrospettivo multicentrico nella psoriasi moderato-grave

Author

Esposito, M, Vagnozzi, E, Di Caprio, R, Assorgi, C, Bellinato, F, Brianti, P, Burlando, M, Brunasso, G, Caccavale, S, Caldarola, G, Campione, E, Calzavara-Pinton, P, Campanati, A, Carrera, C, Carugno, A, Cozzani, E, Costanzo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Diotallevi, F, Fargnoli, M, Gaiani, F, Giunta, A, Malagoli, P, Marzano, A, Megna, M, Mercuri, S, Mortato, E, Narcisi, A, Orsini, D, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Loconsole, F, Gisondi, P, Balato, A, Carrera, CG, Fargnoli, MC, Marzano, AV, Mercuri, SR, Richetta, AG, Esposito, M, Vagnozzi, E, Di Caprio, R, Assorgi, C, Bellinato, F, Brianti, P, Burlando, M, Brunasso, G, Caccavale, S, Caldarola, G, Campione, E, Calzavara-Pinton, P, Campanati, A, Carrera, C, Carugno, A, Cozzani, E, Costanzo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Diotallevi, F, Fargnoli, M, Gaiani, F, Giunta, A, Malagoli, P, Marzano, A, Megna, M, Mercuri, S, Mortato, E, Narcisi, A, Orsini, D, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Loconsole, F, Gisondi, P, Balato, A, Carrera, CG, Fargnoli, MC, Marzano, AV, Mercuri, SR, and Richetta, AG

Abstract

Bimekizumab è un anticorpo monoclonale umanizzato, recentemente approvato per il trattamento della psoriasi a placche moderato-grave, inibitore selettivo delle isoforme dell’interleuchina-17A e F. Le esperienze real-life riguardanti l’utilizzo del farmaco sono limitate ed il profilo del paziente con riposta più elevata PASI100 cioè super responder SR non è stato analizzato. Presentiamo questo studio multicentrico, retrospettivo volto a disegnare il profilo del paziente che beneficia maggiormente del trattamento con bimekizumab, considerando come SR coloro che raggiungono PASI 100 alla settimana-4 e 16. Sono stati studiati pazienti adulti affetti da psoriasi moderato-grave, trattati con bimekizumab per almeno 16 settimane presso 21 centri dermatologici italiani, secondo regole di appropriatezza AIFA e in accordo con la scheda tecnica del farmaco. Endpoints di efficacia erano PASI75, PASI90 e PASI100 alla settimana 4 e 16, ed in particolare la percentuale di SR ai due tempi. I pazienti che non raggiungevano tale target venivano definiti come non-super responders NSRs. Sono stati studiati 137 pazienti con età media 52,47±15,56 anni, BMI medio 27,43±5,91 e PASI medio al basale di 16,00±9,29. Alla settimana 4 il 72% dei pazienti raggiungeva PASI75, il 50% PASI90, mentre il 43% otteneva PASI100, definendo la popolazione SR alla settimana 4. Alla settimana 16, il 93% dei pazienti raggiungeva PASI75, il 77% PASI90, il 70% dei pazienti risultava essere SR mentre solo il 7% non raggiungeva PASI 75. Sono emerse alcune differenze caratterizzanti pazienti con un più rapido raggiungimento dello stato di SRs alla settimana 4 rispetto alla settimana 16: età ≥46<65, coesistenza di <2 comorbidità e stato naïve a precedenti trattamenti biologici. Considerando alcune caratteristiche clinico-demografiche è stata condotta un’analisi univariata per valutare le differenze tra SR e NSRs. Lo stato di NSR è risultato associato significativamente alla settimana 4 con: BMI≥25 &

Published
2024

19. Melanoma in Children, Adolescents, and Young Adults: The Spanish Cohort of the MELCAYA Consortium

Author

Patricio da Silva-Junior, R.M., primary, Ficapal, J., additional, Potrony, M., additional, Torres, T., additional, Gil, M.E., additional, Bague, J., additional, Mateu, J., additional, Crespi-Payeras, F., additional, Podlipnik, S., additional, Puig, J.A., additional, Aguilera, P., additional, Carrera, C., additional, Alòs, L., additional, Malvehy, J., additional, and Puig, S., additional

Published
2024
Full Text
View/download PDF

27. Consenso de terminología en Microscopía Confocal de Reflectancia en español mediante método Delphi

Author

Abarzua-Araya, A., primary, Bañuls, J., additional, Cabo, H., additional, Carrera, C., additional, Gamo, R., additional, González, S., additional, Jaimes, Natalia, additional, Navarrete-Dechent, C., additional, Pérez, J., additional, Roldán-Marín, R., additional, Segura, S., additional, Yélamos, O., additional, Puig, S., additional, and Malvehy, J., additional

Published
2023
Full Text
View/download PDF

30. A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Author

Gargiulo, L., primary, Ibba, L., additional, Malagoli, P., additional, Amoruso, F., additional, Argenziano, G., additional, Balato, A., additional, Bardazzi, F., additional, Burlando, M., additional, Carrera, C. G., additional, Damiani, G., additional, Dapavo, P., additional, Dini, V., additional, Fabbrocini, G., additional, Franchi, C., additional, Gaiani, F. M., additional, Girolomoni, G., additional, Guarneri, C., additional, Lasagni, C., additional, Loconsole, F., additional, Marzano, A. V., additional, Maurelli, M., additional, Megna, M., additional, Orsini, D., additional, Sampogna, F., additional, Travaglini, M., additional, Valenti, M., additional, Costanzo, A., additional, and Narcisi, A., additional

Published
2023
Full Text
View/download PDF

31. High‐ and intermediate‐risk susceptibility variants in melanoma families from the Mediterranean area: a multicenter cohort from the MelaNostrum Consortium

Author

Pellegrini, C., primary, Cardelli, L., additional, Ghiorzo, P., additional, Pastorino, L., additional, Potrony, M., additional, García‐Casado, Z., additional, Elefanti, L., additional, Stefanaki, I., additional, Mastrangelo, M., additional, Necozione, S., additional, Aguilera, P., additional, Rodríguez‐Hernández, A., additional, Di Nardo, L., additional, Rocco, T., additional, Del Regno, L., additional, Badenas, C., additional, Carrera, C., additional, Malvehy, J., additional, Requena, C., additional, Bañuls, J., additional, Stratigos, A. J., additional, Peris, K., additional, Menin, C., additional, Calista, D., additional, Nagore, E., additional, Puig, S., additional, Landi, M. T., additional, and Fargnoli, M. C., additional

Published
2023
Full Text
View/download PDF

33. Concordance of in vivo reflectance confocal microscopy and horizontal‐sectioning histology in skin tumours.

Author

Perino, F., Suarez, R., Perez‐Anker, J., Carrera, C., Rezze, G. G., Primiero, C. A., Alos, L. L., Díaz, A., Barreiro, A., Puig, S., Peris, K., and Malvehy, J.

Subjects
CONFOCAL microscopy, BASAL cell carcinoma, REFLECTANCE, TUMORS, HISTOLOGY, DYSPLASTIC nevus syndrome, SKIN cancer
Abstract

Background: In vivo reflectance confocal microscopy (RCM) enables the study of architectural and cytological aspects in horizontal sections, which closely correlate with histologic features. However, traditional histopathological vertical sections cannot totally reproduce the image of the in vivo RCM horizontal section. Objective: To evaluate the concordance between in vivo RCM and histopathologic transverse sections for melanocytic lesions, basal cell carcinoma and seborrheic keratoses. Methods: Prospectively collected benign melanocytic and non‐melanocytic tumours diagnosed by dermoscopy were evaluated for common RCM features and compared to histopathology in horizontal sections with haematoxylin and eosin staining. Results: A total of 44 skin tumours including 19 melanocytic lesions (nine compound, five junctional and five intradermal nevi), 12 basal cell carcinomas and 13 seborrheic keratoses were collected in the Department of Dermatology of Hospital Clinic of Barcelona. The RCM features that had statistically significant agreement with the histopathological horizontal sections were the preserved and visible honeycomb pattern, well defined DEJ, small bright particles, dermal nests, tumour islands and dark silhouettes, clefting, collagen bundles, thickened collagen bundles and cytologic atypia. Conclusions: Histopathology evaluation of horizontal sections of skin tumours can be correlated with main RCM findings. The results of this study have improved the understanding and interpretation of RCM features in relation to skin tumours, thus reinforcing the utility of RCM as a diagnostic tool. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS).

Author

Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Argenziano, G., Balato, A., Bardazzi, F., Burlando, M., Carrera, C. G., Damiani, G., Dapavo, P., Dini, V., Fabbrocini, G., Franchi, C., Gaiani, F. M., Girolomoni, G., Guarneri, C., Lasagni, C., Loconsole, F., and Marzano, A. V.

Subjects
PSORIASIS, PATIENT experience, PATIENTS' attitudes
Abstract

This article examines the effectiveness of risankizumab, a medication used to treat moderate-to-severe plaque psoriasis. The study found that risankizumab was effective in improving psoriasis symptoms, with a high percentage of patients experiencing significant improvement and complete skin clearance. The study also found that patients who had not previously been treated with biologic drugs and those with a shorter disease history had better responses to the treatment. However, the study has some limitations, and further research is needed to fully understand the long-term effects of risankizumab on psoriasis. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach

Author

De Simone, C, Dapavo, P, Malagoli, P, Martella, A, Campanati, A, Campione, E, Errichetti, E, Franchi, C, Gambardella, A, Megna, M, Osti, F, Ribero, S, Zagni, G, Calzavara-Pinton, P, Fabbrocini, G, Amoruso, G, Baglieri, F, Biamonte, A, Bianchelli, T, Bigi, L, Bortoli, J, Brunetti, B, Buligan, C, Cagni, E, Calderoni, O, Caputo, A, Carrera, C, Carugno, A, Chersi, K, Cicchelli, S, De Natale, F, Di Maria, D, Ferrari, A, Fogli, E, Forconi, R, Galeazzi, A, Giovannini, A, Giura, M, Iuculano, M, Lazzaretti, G, Leporati, C, Magnanini, M, Marconi, B, Maruccia, A, Miglietta, R, Minuti, A, Mocci, L, Modica, S, Narcisi, A, Odorici, G, Pazzaglia, M, Peila, R, Pertusi, G, Pezza, M, Pezzullo, E, Puccia, N, Raulo, U, Rossi, M, Rusignuolo, S, Sapienza, G, Savarese, C, Scalisi, M, Strippoli, D, Stroppiana, E, Tiberio, R, Trischitta, A, Tucci, M, Vaira, F, Verrone, A, Villa, L, Zagni, F, Zoccali, A, De Simone C., Dapavo P., Malagoli P., Martella A., Campanati A., Campione E., Errichetti E., Franchi C., Gambardella A., Megna M., Osti F., Ribero S., Zagni G., Calzavara-Pinton P., Fabbrocini G., Amoruso G. F., Baglieri F., Biamonte A. S., Bianchelli T., Bigi L., Bortoli J., Brunetti B., Buligan C., Cagni E., Calderoni O., Caputo A., Carrera C. G., Carugno A., Chersi K., Cicchelli S., De Natale F., Di Maria D., Ferrari A. S., Fogli E., Forconi R., Galeazzi A., Giovannini A., Giura M. T., Iuculano M., Lazzaretti G., Leporati C., Magnanini M., Marconi B., Maruccia A., Miglietta R., Minuti A., Mocci L., Modica S., Narcisi A., Odorici G., Pazzaglia M., Peila R., Pertusi G., Pezza M., Pezzullo E., Puccia N., Raulo U., Rossi M., Rusignuolo S., Sapienza G., Savarese C., Scalisi M., Strippoli D., Stroppiana E., Tiberio R., Trischitta A., Tucci M. G., Vaira F., Verrone A., Villa L., Zagni F., Zoccali A., De Simone, C, Dapavo, P, Malagoli, P, Martella, A, Campanati, A, Campione, E, Errichetti, E, Franchi, C, Gambardella, A, Megna, M, Osti, F, Ribero, S, Zagni, G, Calzavara-Pinton, P, Fabbrocini, G, Amoruso, G, Baglieri, F, Biamonte, A, Bianchelli, T, Bigi, L, Bortoli, J, Brunetti, B, Buligan, C, Cagni, E, Calderoni, O, Caputo, A, Carrera, C, Carugno, A, Chersi, K, Cicchelli, S, De Natale, F, Di Maria, D, Ferrari, A, Fogli, E, Forconi, R, Galeazzi, A, Giovannini, A, Giura, M, Iuculano, M, Lazzaretti, G, Leporati, C, Magnanini, M, Marconi, B, Maruccia, A, Miglietta, R, Minuti, A, Mocci, L, Modica, S, Narcisi, A, Odorici, G, Pazzaglia, M, Peila, R, Pertusi, G, Pezza, M, Pezzullo, E, Puccia, N, Raulo, U, Rossi, M, Rusignuolo, S, Sapienza, G, Savarese, C, Scalisi, M, Strippoli, D, Stroppiana, E, Tiberio, R, Trischitta, A, Tucci, M, Vaira, F, Verrone, A, Villa, L, Zagni, F, Zoccali, A, De Simone C., Dapavo P., Malagoli P., Martella A., Campanati A., Campione E., Errichetti E., Franchi C., Gambardella A., Megna M., Osti F., Ribero S., Zagni G., Calzavara-Pinton P., Fabbrocini G., Amoruso G. F., Baglieri F., Biamonte A. S., Bianchelli T., Bigi L., Bortoli J., Brunetti B., Buligan C., Cagni E., Calderoni O., Caputo A., Carrera C. G., Carugno A., Chersi K., Cicchelli S., De Natale F., Di Maria D., Ferrari A. S., Fogli E., Forconi R., Galeazzi A., Giovannini A., Giura M. T., Iuculano M., Lazzaretti G., Leporati C., Magnanini M., Marconi B., Maruccia A., Miglietta R., Minuti A., Mocci L., Modica S., Narcisi A., Odorici G., Pazzaglia M., Peila R., Pertusi G., Pezza M., Pezzullo E., Puccia N., Raulo U., Rossi M., Rusignuolo S., Sapienza G., Savarese C., Scalisi M., Strippoli D., Stroppiana E., Tiberio R., Trischitta A., Tucci M. G., Vaira F., Verrone A., Villa L., Zagni F., and Zoccali A.

Abstract

Background: Although long-term management of psoriasis is paramount, this approach is challenging in clinical practice. In the recent PSO-LONG trial, a fixed-dose combination of betamethasone dipropionate (BD) and calcipotriol (Cal) foam applied twice a week on non-consecutive days for 52 weeks (proactive treatment) reduced the risk of relapse. However, the role of Cal/BD foam in the long-term management of psoriasis needs further clarifications. The ProActive Management (PAM) program, a nationwide Italian project, aims at reaching a consensus on the role of proactive management of psoriasis. Methods: A steering committee generated some statements through the nominal group technique (NGT). The statements were voted by an expert panel in an adapted Delphi voting process. Results: Eighteen statements were proposed, and the majority of them (14/18) reached a consensus during the Delphi voting. The need to provide long-term proactive topical treatment to reduce the risk of relapse for the treatment of challenging diseases sites or in patients where phototherapy or systemic therapies are contraindicated/ineffective was widely recognized. A consensus was reached about the possibility to associate the proactive treatment with systemic and biological therapies, without the need for dose intensification, thus favoring a prolonged remission. Moreover, the proactive treatment was recognized as more effective than weekend therapy in increasing time free from relapses. Approaches to improve adherence, on the other hand, need further investigation. Conclusions: The inclusion in guidelines of a proactive strategy among the effective treatment options will be a fundamental step in the evolution of a mild-moderate psoriasis therapeutic approach.

Published
2022

43. Concordance of in vivo reflectance confocal microscopy and horizontal-sectioning histology in skin tumours

Author

Perino, Franco, Suarez, R, Perez-Anker, J, Carrera, C, Rezze, G G, Primiero, C A, Alos, L L, Díaz, A, Barreiro, A, Puig, S, Peris, Ketty, Malvehy, J, Perino, F, Peris, K (ORCID:0000-0002-5237-0463), Perino, Franco, Suarez, R, Perez-Anker, J, Carrera, C, Rezze, G G, Primiero, C A, Alos, L L, Díaz, A, Barreiro, A, Puig, S, Peris, Ketty, Malvehy, J, Perino, F, and Peris, K (ORCID:0000-0002-5237-0463)

Abstract

Background: In vivo reflectance confocal microscopy (RCM) enables the study of architectural and cytological aspects in horizontal sections, which closely correlate with histologic features. However, traditional histopathological vertical sections cannot totally reproduce the image of in vivo RCM horizontal section. Objective: To evaluate the concordance between in vivo RCM and histopathologic transverse sections for melanocytic lesions, basal cell carcinoma, and seborrheic keratoses. Methods: Prospectively collected benign melanocytic and non-melanocytic tumours diagnosed by dermoscopy were evaluated for common RCM features and compared to histopathology in horizontal sections with haematoxylin and eosin staining. Results: A total of 44 skin tumours including 19 melanocytic lesions (9 compound, 5 junctional and 5 intradermal nevi), 12 basal cell carcinomas and 13 seborrheic keratoses were collected in the Department of Dermatology of Hospital Clinic of Barcelona. The RCM features that had statistically significant agreement with the histopathological horizontal sections were the preserved and visible honeycomb pattern, well-defined DEJ, small bright particles, dermal nests, tumour islands and dark silhouettes, clefting, collagen bundles, thickened collagen bundles and cytologic atypia. Conclusions: Histopathology evaluation of horizontal sections of skin tumours can be correlated with main RCM findings. The results of this study have improved the understanding and interpretation of RCM features in relation to skin tumours, thus reinforcing the utility of RCM as a diagnostic tool.

Published
2023

44. Genomics of perivascular space burden unravels early mechanisms of cerebral small vessel disease.

Author

Duperron, M-G, Knol, MJ, Le Grand, Q, Evans, TE, Mishra, A, Tsuchida, A, Roshchupkin, G, Konuma, T, Trégouët, D-A, Romero, JR, Frenzel, S, Luciano, M, Hofer, E, Bourgey, M, Dueker, ND, Delgado, P, Hilal, S, Tankard, RM, Dubost, F, Shin, J, Saba, Y, Armstrong, NJ, Bordes, C, Bastin, ME, Beiser, A, Brodaty, H, Bülow, R, Carrera, C, Chen, C, Cheng, C-Y, Deary, IJ, Gampawar, PG, Himali, JJ, Jiang, J, Kawaguchi, T, Li, S, Macalli, M, Marquis, P, Morris, Z, Muñoz Maniega, S, Miyamoto, S, Okawa, M, Paradise, M, Parva, P, Rundek, T, Sargurupremraj, M, Schilling, S, Setoh, K, Soukarieh, O, Tabara, Y, Teumer, A, Thalamuthu, A, Trollor, JN, Valdés Hernández, MC, Vernooij, MW, Völker, U, Wittfeld, K, Wong, TY, Wright, MJ, Zhang, J, Zhao, W, Zhu, Y-C, Schmidt, H, Sachdev, PS, Wen, W, Yoshida, K, Joutel, A, Satizabal, CL, Sacco, RL, Bourque, G, CHARGE consortium, Lathrop, M, Paus, T, Fernandez-Cadenas, I, Yang, Q, Mazoyer, B, Boutinaud, P, Okada, Y, Grabe, HJ, Mather, KA, Schmidt, R, Joliot, M, Ikram, MA, Matsuda, F, Tzourio, C, Wardlaw, JM, Seshadri, S, Adams, HHH, Debette, S, Duperron, M-G, Knol, MJ, Le Grand, Q, Evans, TE, Mishra, A, Tsuchida, A, Roshchupkin, G, Konuma, T, Trégouët, D-A, Romero, JR, Frenzel, S, Luciano, M, Hofer, E, Bourgey, M, Dueker, ND, Delgado, P, Hilal, S, Tankard, RM, Dubost, F, Shin, J, Saba, Y, Armstrong, NJ, Bordes, C, Bastin, ME, Beiser, A, Brodaty, H, Bülow, R, Carrera, C, Chen, C, Cheng, C-Y, Deary, IJ, Gampawar, PG, Himali, JJ, Jiang, J, Kawaguchi, T, Li, S, Macalli, M, Marquis, P, Morris, Z, Muñoz Maniega, S, Miyamoto, S, Okawa, M, Paradise, M, Parva, P, Rundek, T, Sargurupremraj, M, Schilling, S, Setoh, K, Soukarieh, O, Tabara, Y, Teumer, A, Thalamuthu, A, Trollor, JN, Valdés Hernández, MC, Vernooij, MW, Völker, U, Wittfeld, K, Wong, TY, Wright, MJ, Zhang, J, Zhao, W, Zhu, Y-C, Schmidt, H, Sachdev, PS, Wen, W, Yoshida, K, Joutel, A, Satizabal, CL, Sacco, RL, Bourque, G, CHARGE consortium, Lathrop, M, Paus, T, Fernandez-Cadenas, I, Yang, Q, Mazoyer, B, Boutinaud, P, Okada, Y, Grabe, HJ, Mather, KA, Schmidt, R, Joliot, M, Ikram, MA, Matsuda, F, Tzourio, C, Wardlaw, JM, Seshadri, S, Adams, HHH, and Debette, S

Abstract

Perivascular space (PVS) burden is an emerging, poorly understood, magnetic resonance imaging marker of cerebral small vessel disease, a leading cause of stroke and dementia. Genome-wide association studies in up to 40,095 participants (18 population-based cohorts, 66.3 ± 8.6 yr, 96.9% European ancestry) revealed 24 genome-wide significant PVS risk loci, mainly in the white matter. These were associated with white matter PVS already in young adults (N = 1,748; 22.1 ± 2.3 yr) and were enriched in early-onset leukodystrophy genes and genes expressed in fetal brain endothelial cells, suggesting early-life mechanisms. In total, 53% of white matter PVS risk loci showed nominally significant associations (27% after multiple-testing correction) in a Japanese population-based cohort (N = 2,862; 68.3 ± 5.3 yr). Mendelian randomization supported causal associations of high blood pressure with basal ganglia and hippocampal PVS, and of basal ganglia PVS and hippocampal PVS with stroke, accounting for blood pressure. Our findings provide insight into the biology of PVS and cerebral small vessel disease, pointing to pathways involving extracellular matrix, membrane transport and developmental processes, and the potential for genetically informed prioritization of drug targets.

Published
2023

45. On the Valorization of Arbutus unedo L. Pomace : Polyphenol Extraction and Development of Novel Functional Cookies

Author

Duarte, H., Carrera, C., Aliaño-González, M. J., Gutiérrez-Escobar, R., Jiménez-Hierro, M. J., Palma, M., Galego, L., Romano, A., Medronho, Bruno, Duarte, H., Carrera, C., Aliaño-González, M. J., Gutiérrez-Escobar, R., Jiménez-Hierro, M. J., Palma, M., Galego, L., Romano, A., and Medronho, Bruno

Abstract

The fruits of Arbutus unedo L. have a crimson colour and are enriched with remarkable concentrations of bioactive compounds such as anthocyanins and polyphenols. These fruits are commonly used in the production of a Portuguese Protected Geographical Indication distillate called “Aguardente de Medronho”. During this process, a solid pomace is generated and presently discarded without valuable applications. In this work, two strategies have been developed for the valorisation of A. unedo pomace. The first approach considers the extraction of polyphenols from this by-product through the optimization of an ultrasound-assisted method using a Box-Behnken design coupled with response surface methodology. The results indicate that the temperature and the percentage of methanol, along with their interaction, significantly influence the total concentration of polyphenols and the antioxidant activity of the extracts obtained. The optimal conditions identified consider the extraction of 0.5 g of sample with 20 mL of a solvent containing 74% MeOH (aq), at a pH of 4.8, maintained at 70 °C for 15 min. On the other hand, the second valorisation strategy considered the use of A. unedo pomace in the development of functional cookies. The incorporation of 15–20% pomace in the cookie formulation was well-received by consumers. This incorporation results in an intake of ca. 6.55 mg of polyphenols per gram of cookie consumed, accompanied by an antioxidant activity of 4.54 mg Trolox equivalents per gram of cookie consumed. Overall, these results encourage the employment of A. unedo pomace either as a reliable source of extracts enriched in polyphenols or as a nutraceutical active ingredient in functional cookies, thereby positively impacting human health.

Published
2023
Full Text
View/download PDF

46. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, Costanzo, Antonio, Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, and Costanzo, Antonio

Abstract

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

Published
2023

49. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

Author

Fargnoli, Maria Concetta, Bardazzi, F., Bianchi, L., Dapavo, P., Fabbrocini, G., Gisondi, P., Micali, G., Offidani, A. M., Pellacani, G., Skroza, N., Angileri, R. G., Burlando, M., Campanati, A., Carrera, C. G., Chiricozzi, Andrea, Conti, A., Simone, C. D., Di Lernia, V., Errichetti, E., Galluzzo, M., Guarneri, C., Lasagni, C., Lembo, S., Loconsole, F., Megna, M., Musumeci, M. L., Prignano, F., Richetta, A. G., Trovato, E., Venturini, M., Peris, Ketty, Pinton, P. C., Fargnoli M. C., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Fargnoli, Maria Concetta, Bardazzi, F., Bianchi, L., Dapavo, P., Fabbrocini, G., Gisondi, P., Micali, G., Offidani, A. M., Pellacani, G., Skroza, N., Angileri, R. G., Burlando, M., Campanati, A., Carrera, C. G., Chiricozzi, Andrea, Conti, A., Simone, C. D., Di Lernia, V., Errichetti, E., Galluzzo, M., Guarneri, C., Lasagni, C., Lembo, S., Loconsole, F., Megna, M., Musumeci, M. L., Prignano, F., Richetta, A. G., Trovato, E., Venturini, M., Peris, Ketty, Pinton, P. C., Fargnoli M. C., Chiricozzi A. (ORCID:0000-0002-6739-0387), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = “strongly disagree” to 5 = “strongly agree”) using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form “main principles” and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.

Published
2023

50. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, Giacomo, Campanati, A., Campione, E., Carrera, C. G., Carugno, A., Cristaudo, A., Cusano, F., Dapavo, P., Dattola, Carmelo Alberto, De Simone, Clara, Gaiani, F. M., Gisondi, P., Giunta, A., Loconsole, F., Maione, V., Mortato, E., Marzano, A. V., Maurelli, M., Megna, M., Mercuri, S. R., Offidani, A., Orsini, Diego, Parodi, A., Pellacani, G., Potestio, L., Quaglino, P., Richetta, A. G., Romano, Federica, Sena, P., Venturini, M., Malagoli, P., Costanzo, Rosa Maria Alba, Caldarola G. (ORCID:0000-0002-8837-9232), Dattola A., De Simone C. (ORCID:0000-0002-0898-0045), Orsini D., Romano F., Costanzo A., Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, Giacomo, Campanati, A., Campione, E., Carrera, C. G., Carugno, A., Cristaudo, A., Cusano, F., Dapavo, P., Dattola, Carmelo Alberto, De Simone, Clara, Gaiani, F. M., Gisondi, P., Giunta, A., Loconsole, F., Maione, V., Mortato, E., Marzano, A. V., Maurelli, M., Megna, M., Mercuri, S. R., Offidani, A., Orsini, Diego, Parodi, A., Pellacani, G., Potestio, L., Quaglino, P., Richetta, A. G., Romano, Federica, Sena, P., Venturini, M., Malagoli, P., Costanzo, Rosa Maria Alba, Caldarola G. (ORCID:0000-0002-8837-9232), Dattola A., De Simone C. (ORCID:0000-0002-0898-0045), Orsini D., Romano F., and Costanzo A.

Abstract

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results